Skip to content

Clinical Study of Yiqi Huoxue Xiaoxian Decoction for Treating Pediatric Adenoid Hypertrophy Syndrome with Qi Deficiency and Blood Stasis

A prospective observational real-world study on the treatment of adenoid hypertrophy with Qi deficiency and blood stasis syndrome in children with the Formula of Tonifying Qi Promoting Blood Circulation and eliminating glands

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001525
Enrollment
Unknown
Registered
2025-07-30
Start date
2024-02-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenoid hypertrophy

Interventions

Western Medicine:Use the leukotriene receptor antagonist montelukast or nasal hormones such as mometasone furoate nasal spray, and provide symptomatic treatment for comorbidities, such as anti-infecti
Traditional Chinese medicine:Yiqi Huoxue Xiaoxian Formula
Surgical:Adenoidectomy
External treatment:External treatment with traditional Chinese medicine application

Sponsors

Children's Hospital Affiliated with Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 10 Years

Inclusion criteria

Inclusion criteria: 1)The child meets the Western medicine diagnostic criteria for adenoid hypertrophy. 2)The child meets the Traditional Chinese Medicine diagnostic criteria for adenoid hypertrophy with the syndrome of qi deficiency and blood stasis. 3)The child is between 3 and 10 years old with no gender restriction. 4)The child has good compliance and can cooperate with the relevant examinations. 5)The childs parent or legal guardian has signed the informed consent form and volunteered to participate in the study.

Exclusion criteria

Exclusion criteria: 1)Individuals who do not meet the inclusion criteria; 2)Children who are allergic to the medication or have contraindications to the related drugs; 3)Children who in the investigator's judgment have past or current diseases that may affect their participation in the trial or the outcome of the; 4)Children with severe underlying diseases of the heart liver kidneys digestive system or hematopoietic system or with mental disorders.

Design outcomes

Primary

MeasureTime frame
The main clinical manifestations, remission rate and remission time;A/N ratio;

Secondary

MeasureTime frame
Combined utilization rate of antibiotics;Remission rate of secondary clinical symptoms;

Countries

China

Contacts

Public Contactzhang xinyue

Children's Hospital Zhejiang University School of Medicine

cicelyxyz@zju.edu.cn15968806812

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026